Selected portfolios: Santa Ana Bio, Rgenta, Tune, MediLink, AllianThera, ABM Tx, Base Tx, Bristar, Unicet, Migrasome, Velavigo.• Lead a cross-functional team to identify new trends in therapeutics through systematic analyses of unmet medical needs and new technology platforms (BsAb, ADC, TRT, cell and gene therapy, degrader, mRNA, siRNA, RNA-targeting small molecule, new delivery tool, etc.)• Search and evaluate early stage investment deals in a variety of therapeutics, including immunology, oncology, CNS and metabolic diseases. • Incubate innovative translational projects from academia and recruit team members.• Manage 30+ portfolio companies around the world and provide value add services, serving as directors and observers on the board, facilitating out-licensing deals.• Establish external collaborations with international VC/PE funds, big pharma, biotech incubators and academia.

• Built strong cross-functional teams from R&D and clinical development, delivering comprehensive strategies for successful expansion into new therapeutic areas, such as autoimmune diseases and hematological cancers.• Led in-depth reviews of novel targets, MoAs and modalities, proposing 10+ internal pipelines, external innovation projects and organizational support, managing early research programs.• Conducted due diligence and analyzed competitive landscape for 10+ in-license opportunities, collaborating closely with business development and clinical functions.

• Invented new enzymatic solutions, including 10 global patents/product launches, to increase efficiency for biopharma, animal health, food and wastewater industries.• Led cross-functional teams to identify new areas for business growth in China, evaluating both technological feasibility and marketing potential.• Supported the Head of Global Innovation and Head of Regional Business Development on strategy formulation and technical/business reviews with senior leadership.• Collaborated with internal functions, academia and regulatory institutions for biotech innovations, such as high throughput screening technology and synthetic biology.• Managed multiple research projects/initiatives and supervised team members.

• Led a group of scientists and demonstrated the impact of amino acid restriction on inflammation and aging through GCN2 kinase pathway, reported by the Washington Post.• Established the protective function of the small molecule halofuginone in ischemia injury.• Developed in vivo protocols of inflammation induced by bacterial pathogens.

• Investigated the mechanism of cortisol-induced obesity, using an adipocyte-specific glucocorticoid receptor knockout mouse, and revealed a connection with PGC-1alpha.• Wrote three grants and developed a protocol for inducing obesity by oral delivery.• Collaborated with colleagues to discover the role of Rho kinases in metabolic diseases.